ExtraSuperTadarise is a compound preparation whose main ingredients are Tadalafil and Dapoxetine. It is used for the treatment of male erectile dysfunction (ED) and premature ejaculation (PE).
Precautions for Taking ExtraSuperTadarise
Contraindications
Concurrent use of any form of nitrate medications (e.g., nitroglycerin, isosorbide mononitrate, etc.).
Patients with severe cardiovascular diseases or unstable angina pectoris.
Individuals allergic to Tadalafil or Dapoxetine.
Patients with severe liver function impairment.
Concurrent use of potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, etc.).
Medication Use in Special Populations
Patients with cardiovascular diseases: It is necessary to evaluate whether the heart condition is suitable for sexual activity.
Patients with hepatic insufficiency: Dosage adjustment is required for patients with mild to moderate hepatic insufficiency; use is contraindicated in patients with severe hepatic insufficiency.
Patients with renal insufficiency: For patients with a creatinine clearance rate < 30 mL/min, the maximum dosage should not exceed 10 mg.
Elderly patients: Patients aged 65 years and above should use this medication with caution.
Administration Regimen
The recommended dosage is once daily, taken as a whole tablet with water; it can be taken with food.
Taking it 30-60 minutes before sexual activity yields the best effect.
Do not exceed one dose within 24 hours.
Avoid taking it with grapefruit juice.
Drug Interactions
Nitrate medications: Concurrent use is absolutely contraindicated, as it may cause life-threatening hypotension.
Alpha-blockers: May enhance the blood pressure-lowering effect.
CYP3A4 inhibitors: May increase the blood concentration of Tadalafil.
Antidepressants: May interact with Dapoxetine.
Medication Monitoring for ExtraSuperTadarise
Routine Monitoring Items
Cardiovascular function: Monitoring of blood pressure and heart rate.
Liver function: Regular examination of transaminases.
Renal function: Evaluation of creatinine clearance rate.
Visual function: Monitoring of abnormal color perception.
Special Monitoring
Evaluation of sexual function improvement: Use of the International Index of Erectile Function (IIEF) questionnaire.
Evaluation of premature ejaculation improvement: Recording of intravaginal ejaculatory latency time (IELT).
Evaluation of drug tolerance: Recording of the occurrence of adverse reactions.
Self-Monitoring
Instruct patients to identify and report the following conditions in a timely manner:
Cases of priapism (abnormal erection).
Symptoms of cardiovascular discomfort.
Changes in vision.
Mood swings.
